Thyrocare Technologies Limited announced its unaudited standalone and consolidated financial results for Q3 2026. The Board also approved an amendment to the Code of Conduct for regulating, monitoring, and reporting trading by designated persons and their immediate relatives. Results are subject to limited review. The board meeting concluded at 4:05 P.M. The amended PIT code is available on the company website.
Q3 2026 Financial Results
Thyrocare Technologies Limited has released its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. These results have undergone a limited review. The decision regarding the results was made during a board meeting held on January 28, 2026.
Amendment to Trading Code
The Board has also approved an amendment to the “Code of Conduct to Regulate, Monitor, and Report Trading by Designated Persons and their Immediate Relatives” (“PIT Code”). The amended PIT Code is available on the Company’s website at https://investor.thyrocare.com/policies-codes/.
Financial Performance Highlights (Standalone)
Key figures from the standalone financial results include:
- Total Income: ₹185.91 crores for the quarter ended December 31, 2025.
- Profit before exceptional items and tax: ₹42.59 crores for the quarter.
- Profit for the period: ₹26.15 crores.
- Total Comprehensive Income: ₹26.03 crores.
Financial Performance Highlights (Consolidated)
Key figures from the consolidated financial results include:
- Total Income: ₹200.51 crores for the quarter ended December 31, 2025.
- Profit before exceptional items: ₹41.27 crores for the quarter.
- Profit for the period: ₹28.05 crores.
- Total Comprehensive Income: ₹27.91 crores.
Board Meeting Conclusion
The board meeting to approve these results commenced at 3:30 P.M. and concluded at 4:05 P.M. on January 28, 2026.
Source: BSE
